◆ 会议时间:2023年11月2日至5日
◆ 会议地点:法国 马赛
◆ 会议简介:
2023年第15届欧洲泌尿系统肿瘤多学科大会(EMUC2023)将于2023年11月2日至5日在法国马赛举行,EMUC是欧洲最大的泌尿系统肿瘤学会议,由欧洲肿瘤内科学会(ESMO)、欧洲放射治疗与肿瘤学会(ESTRO)和欧洲泌尿外科协会(EAU)/欧洲泌尿外科学院(ESU)合作举办。为期四天的会议,来自欧洲以及欧洲以外其他国家众多的肿瘤学家、放射科医师、病理学家和泌尿科医师将分享他们的知识与经验,并对泌尿生殖系统肿瘤(GU)的最新研究进展进行认真评估和提出见解-领域国际医学会议网。EMUC至今已成举办十二届,现已建立了作为专业和科学交流领先平台宣的声誉,它不仅对有争议的问题进行批判性的审视,而且还对临床实践中的实际见解进行审视评估。无论是关于创新治疗的重要辩论,标准治疗的局限性还是新研究成果的影响,EMUC都是一次前沿的协作会议,旨在确定最佳疗法并解决临床实践中的空白。未经许可禁止复制摘录转载本站任何内容-国际医学会议网(lingyuint.com)
EMUC科学计划将包括预防、诊断和管理泌尿生殖系统(GU)癌症方面的当前相关进展,其范围将包括世界卫生组织对膀胱癌的最新分类、前列腺癌的现代成像、非肌层浸润性膀胱癌的综合系统治疗、主要试验的最新进展、该领域的最新分子发展等。在EMUC21上,还将解决当前存在的争议和挑战,例如优化利用诊断工具(包括分子标记物)以实现个性化治疗方法,为患者实现最大利益。
The 15th European Multidisciplinary Congress on Urological Cancers (EMUC23)
Date: 2-5 November, 2023
Venue: Marseille, France
摘要征文投稿:
Abstract submission open |
1 March 2023 |
Abstract submission deadline |
1 August 2023, 23:59 CET |
点此提交摘要>>>Submit Abstract>>>
Download the abstract submission rules here
Topics EMUC
Prostate Cancer, Localised – Basic Research & Trials
Prostate Cancer, Localised – Diagnosis
Prostate Cancer, Localised – Diagnosis, Pathology & Biopsies
Prostate Cancer, Localised – Treatment
Prostate Cancer, Localised – Follow up
Prostate Cancer, Localised – Follow up, Clinical / Prognosis
Prostate Cancer, Localised – Follow up, Quality of life / Patient reported outcomes
Prostate Cancer, Locally advanced – Basic Research & Trials
Prostate Cancer, Locally advanced – Diagnosis
Prostate Cancer, Locally advanced – Diagnosis, Pathology & Biopsies
Prostate Cancer, Locally advanced – Treatment
Prostate Cancer, Locally advanced – Follow up
Prostate Cancer, Locally advanced – Follow up, Clinical / Prognosis
Prostate Cancer, Locally advanced – Follow up, Quality of life / Patient reported outcomes
Prostate Cancer, Metastatic – Basic Research & Trials
Prostate Cancer, Metastatic – Diagnosis
Prostate Cancer, Metastatic – Diagnosis, Pathology & Biopsies
Prostate Cancer, Metastatic – Treatment
Prostate Cancer, Metastatic – Follow up
Prostate Cancer, Metastatic – Follow up, Clinical / Prognosis
Prostate Cancer, Metastatic – Follow up, Quality of life / Patient reported outcomes
Renal Tumour – Basic Research & Trials
Renal Tumour – Diagnosis
Renal Tumour – Treatment
Renal Tumour – Follow up, Clinical / Prognosis
Renal Tumour – Follow up
Renal Tumour – Follow up, Quality of life / Patient reported outcomes
Renal Tumour – Diagnosis, Pathology & Biopsies
Urothelial Cancer – Basic Research & Trials
Urothelial Cancer – Diagnosis
Urothelial Cancer – Diagnosis, Pathology & Biopsies
Urothelial Cancer – Treatment
Urothelial Cancer – Follow up
Urothelial Cancer – Follow up, Clinical / Prognosis
Urothelial Cancer – Follow up, Quality of life / Patient reported outcomes
Testicular Cancer – Diagnosis
Testicular Cancer – Treatment
Testicular Cancer – Follow up, Clinical / Prognosis
Testicular Cancer – Diagnosis, Pathology & Biopsies
Penile Cancer – Basic Research & Trials
Penile Cancer – Diagnosis
Penile Cancer – Diagnosis, Pathology & Biopsies
Penile Cancer – Treatment
Penile Cancer – Follow up
Penile Cancer – Follow up, Clinical / Prognosis
Penile Cancer – Follow up, Quality of life / Patient reported outcomes
Non-Disease specific
Topics ESUI
Prostate Cancer – Diagnosis, Imaging
Prostate Cancer – Follow up, Imaging
Prostate Cancer – Basic Research & Trials, Imaging
Prostate Cancer – Treatment, Imaging
Renal Tumour – Diagnosis, Imaging
Renal Tumour – Follow up, Imaging
Renal Tumour – Basic Research & Trials, Imaging
Renal Tumour – Treatment, Imaging
Urothelial Cancer – Diagnosis, Imaging
Urothelial Cancer – Follow up, Imaging
Urothelial Cancer – Basic Research & Trials, Imaging
Urothelial Cancer – Treatment, Imaging
Penile Cancer – Diagnosis, Imaging
Penile Cancer – Follow up, Imaging
Penile Cancer – Basic Research & Trials, Imaging
Penile Cancer – Treatment, Imaging
Testicular Cancer – Diagnosis, Imaging
Testicular Cancer – Basic Research & Trials, Imaging
Testicular Cancer – Treatment, Imaging
Testicular Cancer – Follow up, Imaging
Non-Disease specific – Basic Research & Trials, Imaging
Non-Disease specific – Diagnosis, Imaging
Non-Disease specific – Follow up, Imaging
Non-Disease specific – Treatment, Imaging
Publication
The accepted abstracts of EMUC23 are going to be published online in the EMUC resource centre, in the EMUC/ESUI app and as an online supplement by Elsevier on European Urology Open Science. If you do not want your case report(s) or video(s) published online please send an e-mail to emuc@congressconsultants.com.
Please note: Copyright of the abstract(s) is assigned to the EMUC office and any conflicts with any other scientific association will be the sole responsibility of the author(s).
注册费:
What are EMUC23 delegates entitled to?
- Access to the scientific sessions (Friday, Saturday, Sunday)
- Access to the workshops and extras on Thursday (additional registration fee applies)
- Access to the industry sessions
- Access to the exhibition
- A congress bag
- Coffee breaks and lunch breaks
- Access to the content of the EMUC23 Resource Centre
Prices for ESTRO / ESMO / EAU Members
|
Early fee
Until 3 Aug 2023 |
Late fee
4 Aug –
19 Oct 2023 |
Onsite fee
20 Oct –
5 Nov 2023 |
Member |
€520 |
€650 |
€890 |
Junior / Medical Student / Nurse Member |
€205 |
€325 |
€535 |
Patient Advocate |
€190 |
€190 |
€190 |
To qualify for a reduced registration fee, you need to hold an active membership.
Prices for Non-Members
|
Early fee
Until
3 Aug 2023 |
Late fee
4 Aug –
19 Oct 2023 |
Onsite fee
20 Oct 2022 –
5 Nov 2023 |
Delegate |
€650 |
€755 |
€940 |
Resident / Medical Student
/ Full-time Researcher / Nurse* |
€325 |
€435 |
€665 |
* For nurses, medical students, full time researchers and residents (who are not member) a proof of status is required for registration. A proof of status is an official letter, no older then 6 months, written in English by the head of the hospital department on official paper.
Extras
ESU Course (members) |
€85 |
ESU Course (non-members) |
€125 |
Hands-on Training (urologists) |
€60 |
Hands-on Training (residents) |
€40 |
◆ 参会对象:医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。
|